Melanotan II (often abbreviated as MT-II or MT2, sometimes called the “Barbie drug”) is a synthetic peptide analog of the natural hormone α-melanocyte-stimulating hormone (α-MSH). It was developed in the 1990s as a potential tanning agent and successor to Melanotan I (afamelanotide), but it is not approved for any medical or cosmetic use by the FDA, TGA (Australia), HPRA (Ireland), or most other regulatory bodies.
How It Works
Melanotan II acts as a non-selective agonist of melanocortin receptors (primarily MC1R for tanning, but also MC3R, MC4R, and MC5R). This stimulates melanocytes in the skin to produce more eumelanin (the dark pigment), leading to increased pigmentation and a “sunless” tan—even with minimal UV exposure. It can enhance tanning when combined with sun or UV light. Because it crosses into the brain and affects other receptors, it also influences appetite suppression, libido/sexual arousal, and other systems.
- Melanotan I (afamelanotide/Scenesse) is more selective for MC1R, has a linear structure, and is FDA-approved only for a rare light-sensitivity disorder (erythropoietic protoporphyria). It causes slower, more gradual tanning with fewer systemic side effects.
- Melanotan II is a shorter cyclic peptide, generally more potent for tanning at lower doses, but it produces stronger off-target effects (e.g., sexual stimulation via MC4R and appetite loss).
